---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042967"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:20:07.710641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive reports Q1 net income $0.5M, cash $19.8M, OLC PDUFA June 28, 2025

## Summary
- Net income attributable to common stockholders of $0.5M for Q1 2025, vs net loss of $21.2M in Q1 2024.
- Cash and cash equivalents totaled $19.8M as of March 31, 2025.
- OLC NDA under FDA review with PDUFA target action date of June 28, 2025; commercial launch preparation ongoing.
- R&D expenses fell to $2.2M from $6.8M; G&A rose to $5.8M from $2.4M due to launch prep costs.
- Patient survey data presented at NKF and ANNA meetings identified pill burden as primary adherence barrier.

## SEC filing metadata
- accession: 0001213900-25-042967
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/0001213900-25-042967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea0242081-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042967
- JSON: https://secwatch.observer/filing/0001213900-25-042967.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.